A recent report suggests a medication used to strengthen bones may be an ideal complement to treatments used to attack breast cancer cells.
Wired PR News.com – As reported by the Associated Press (AP), use of the bone drug Zometa may help treatments that shrink breast cancer tumors and reduce the need for radical surgery. The drug was also reported to reduce the risk of recurrence of the disease in women in which it developed before they experienced menopause.
As mentioned in the AP report, Zometa is a drug administered to cancer patients to prevent bone loss that may accompany some treatments, and is also used for other conditions. The results of the recent preliminary study, sponsored by drug manufacturer, Novartis AG, were presented on Thursday at a conference on cancer in Texas.
The findings are noted as insufficient enough to warrant changes in medical practice, however, doctors have been stated to view them as significant enough for further research.
Zometa may carry side effects similar to those associated with other drugs used for bone strengthening including muscle pain and the chance of jawbone decay. Treatment can cost around $1,200 per infusion.